TEVA-THEOPHYLLINE SR TABLET (EXTENDED-RELEASE)

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

THEOPHYLLINE

Disponible desde:

TEVA CANADA LIMITED

Código ATC:

R03DA04

Designación común internacional (DCI):

THEOPHYLLINE

Dosis:

300MG

formulario farmacéutico:

TABLET (EXTENDED-RELEASE)

Composición:

THEOPHYLLINE 300MG

Vía de administración:

ORAL

Unidades en paquete:

100/500/1000

tipo de receta:

Prescription

Área terapéutica:

RESPIRATORY SMOOTH MUSCLE RELAXANTS

Resumen del producto:

Active ingredient group (AIG) number: 0103582004; AHFS:

Estado de Autorización:

CANCELLED POST MARKET

Fecha de autorización:

2018-05-08

Ficha técnica

PRODUCT MONOGRAPH
PR
TEVA-THEOPHYLLINE SR
(Theophylline Anhydrous)
100, 200 and 300 mg Tablets (Sustained Release)
Teva Standard
Bronchodilator
Teva Canada Limited
Date of Preparation:
30 Novopharm Court
May 6, 2011
Toronto, Ontario
M1B 2K9
www.tevacanada.com
Control No:
147027
2
Pr
TEVA-THEOPHYLLINE SR
(Theophylline Anhydrous)
100, 200 and 300 mg Tablets (Sustained Release)
Teva Standard
THERAPEUTIC CLASSIFICATION
Bronchodilator
AGTION AND CLINICAL PHARMACOLOGY
TEVA-THEOPHYLLINE SR (theophylline) relieves bronchospasm and
increases flow
rates and vital capacity through the relaxation of the smooth muscle
of the bronchial
airways and pulmonary blood vessels. It also produces other actions
typical of the
xanthine derivatives: coronary vasodilation, diuresis, increase in
gastric secretion, and
cardiac, cerebral and skeletal muscle stimulation. The actions of
theophylline may be
mediated through inhibition of phosphodiesterase and the consequent
increase in
intracellular cyclic adenosine monophosphate, but the exact
mechanism(s) has not been
determined.
Theophylline is usually readily absorbed and distributed into all body
compartments.
Protein binding is approximately 55 to 65 %. The primary site of
metabolism is the liver.
The therapeutic serum concentration range commonly accepted is 10 to
20 _µ_g/mL (55 to
110 _µ_g/mL; levels above 20 _µ_g/mL are associated with toxic
reactions. A number of
variables influence the pharmacokinetics of theophylline. These
include age, disease
state, smoking and concomitant medications. Therefore, the optimum
therapeutic
maintenance dose should be determined by individual titration.
TEVA-THEOPHYLLINE SR (theophylline) are sustained release tablets
which produce
blood levels between 5 to 8 hours after dosing in adults and between 4
to 6 hours after
dosing in children 6 years of age and older. Once the steady state
level has been reached
(3 days), the therapeutic blood levels persist for 12 hours in most
adult patients. The
mean elimination half-life of theophylline in nonsmoking